Relapsed adult acute lymphoblastic leukemia (ALL) is associated with high reinduction mortality, chemotherapy resistance, and rapid progression leading to death. Vincristine sulfate liposome injection (VSLI), sphingomyelin and cholesterol nanoparticle vincristine (VCR), facilitates VCR dose-intensification and densification plus enhances target tissue delivery. We evaluated highdose VSLI monotherapy in adults with Philadelphia chromosome (Ph) -negative ALL that was multiply relapsed, relapsed and refractory to reinduction, and/or relapsed after hematopoietic cell transplantation (HCT).
INTRODUCTION
Adult Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) is a B-or T-cell lineage hematologic malignancy with approximately 2,000 to 2,500 new patients diagnosed annually in the United States. 1 In contrast to children with ALL, the prognosis for adults diagnosed with ALL is poor. [2] [3] [4] Although initial rates of complete response (CR) in adult ALL can achieve 92% following firstline, curative-intent, multiagent chemotherapy in-cluding a corticosteroid, vincristine sulfate (VCR), and an anthracycline, most patients relapse while still on therapy. [4] [5] [6] [7] [8] Second-line chemotherapy can achieve a second remission in approximately 40% of adults following first relapse; however, the vast majority of patients relapse again within months. 4, 5, 9, 10 Adult, Ph-negative ALL in second or greater relapse, that relapses and is refractory to one or more reinduction attempts, and/or relapsed following a hematopoietic cell transplantation (HCT) accounts for approximately 1, United States and is regarded as relatively chemotherapy resistant, incurable, and associated with reinduction mortality rates up to 30%. 3 There are no established standards of care in this setting and limited treatment options.
Vincristine sulfate liposome injection (VSLI; Marqibo, Talon Therapeutics), a sphingomyelin-and cholesterol-based, nanoparticle formulation of the widely used anticancer drug, VCR, was designed to overcome the dosing and pharmacokinetic limitations of standard, nonliposomal VCR. 11 In nonclinical experiments, VSLI had a larger maximum-tolerated dose than standard VCR and demonstrated enhanced mg-per-mg antileukemia activity without additional toxicity. 11-13 VSLI enhanced VCR penetration and concentration in tissues and organs with fenestrated vasculature or involved in the mononuclear phagocyte system, including ALL target tissues (eg, bone marrow, lymph nodes, spleen) and implanted tumors. [11] [12] [13] Based on a clear unmet medical need, the superiority of VSLI over standard VCR in nonclinical models, and encouraging activity attributed to VSLI in the phase 1 dose-ascending trial, 14 we conducted a multinational, pivotal, phase II, single-arm, open-label trial of highdose (2.25 mg/m 2 ), once-per-week VSLI monotherapy in heavily pretreated adults with advanced, relapsed, and refractory B-or T-cell lineage Ph-negative ALL. This study served as the basis for accelerated approval in the United States granted on August 9, 2012.
PATIENTS AND METHODS

Patients
Adults (at least 18 years old) with confirmed Ph-negative ALL in second or greater relapse, or who had progressed following two or more lines of antileukemia chemotherapy (including HCT) were study eligible. Eligible patients had at least one prior CR with a leukemia-free interval of at least 90 days. Patients with residual persistent grade 1 or nonpersistent grade 2 or higher prior VCR-related neuropathy according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 were eligible. Patients with Burkitt's type leukemia, active and uncontrolled CNS ALL, and those eligible for immediate HCT (ie, readily available suitable donor, willingness to undergo HCT, and investigator belief that HCT was a better treatment option than VSLI) were excluded.
Study Oversight and Support
The institutional review board or independent ethics committee of each participating institution approved the study. This study was conducted in accordance with the principles of the World Medical Association's Declaration of Helsinki, the International Conference on Harmonisation Guideline for Good Clinical Practice, and the laws and regulations of the countries in which the research was conducted. All patients provided written, informed consent.
An independent data monitoring committee reviewed the study conduct and safety profile. An independent response review committee (IRRC) was unaware of principal investigator (PI) assessments, corroborated PI response assessments, and calculated response and survival durations. A central laboratory analyzed all bone marrow (BM) samples.
Study Design
Patients received once-per-week VSLI 2.25 mg/m 2 monotherapy based on actual body-surface area and without dose capping. VSLI doses represent the VCR component of the drug. VSLI was administered intravenously via peripheral or central venous access over 60 minutes on days 1, 8, 15, and 22 of a 28-day course in an outpatient or inpatient treatment setting. Hydroxyurea and systemic corticosteroids to control leukocytosis were allowed through day 14 and day 5 of course 1, respectively. Patients received VSLI once per week until response achievement, leukemia progression, toxicity, or decision to pursue other therapy such as HCT. Patients with ongoing response could continue VSLI at the PI discretion.
A protocol-specified VSLI dose-modification algorithm (Appendix Table A1 , online-only) was used to manage persistent grade 2 and any grade 3 or greater nonhematologic toxicity while attempting to maximize cumulative VSLI dosing and achievement of clinical benefit. Dose modification included 1-week dosing breaks and dose reduction.
End Points and Assessments
The protocol-specified primary efficacy end point was the proportion of patients who achieved CR or CR with incomplete recovery of peripheral blood neutrophil counts (Ͻ 1 ϫ 10 9 /L) or platelet counts (Ͻ 100 ϫ 10 9 /L; CRi) based on PI assessment. CRi was included because patients were expected to be heavily pretreated and unlikely to ever normalize their blood counts.
Secondary efficacy end points included CR/CRi duration, overall survival (OS), proportion of patients "bridged" to post-VSLI HCT, overall response rate (CR ϩ CRi ϩ partial remission [PR] ϩ BM blast response [BMB]), and time to CR/CRi achievement. A BMB is a morphologic CR with incomplete recovery of both peripheral blood neutrophil and platelet counts. Efficacy end point criteria were adapted from published reporting standards. 15, 16 Exploratory analyses included assessment of response and survival as functions of baseline patient and disease characteristics. Postinduction minimal residual disease (MRD), based on site-specific flow cytometry analysis of BM, was evaluated posthoc in CR/CRi patients.
Patients underwent standard medical history and physical examination and a 15-point neurologic assessment to proactively identify peripheral neuropathy before each VSLI dose and 30 days after the last dose. BM examination and assessment of documented extramedullary disease were targeted for day 28 of study treatment courses 1 and 2 and every other active treatment course thereafter.
Statistical Analysis
This study was designed to detect a CR/CRi rate at least double the historical rate of 3.6% based on available data in the target population. 3 Achievement of CR/CRi in nine (16%) of 56 patients (95% CI, 7.6 to 28.4) was the predefined threshold for a positive study. The study protocol was later amended to increase the sample size from 56 to 65 to accommodate the collection of pharmacokinetic data.
Efficacy and safety were assessed in patients who received at least one dose of VSLI. Exact two-sided 95% CI were constructed where appropriate. 17 Multivariate logistic regression was applied to analyze CR/CRi prognostic factors. Standard multivariate Cox proportional hazards regression analysis was used to evaluate OS prognostic factors. Analyses were carried out using SAS version 9.1 or higher (SAS Institute, Cary, NC).
RESULTS
Patient and Disease Characteristics
Baseline demographic and disease characteristics are listed in Table 1 . The patient population was clinically advanced and heavily pretreated. Most presented with a large disease burden as reflected by the median BM and peripheral blood blast contents of 82%, more than half had already received three or more lines of therapy, and 45% were refractory to their immediate prior line of antileukemia therapy. Patients had been exposed to a median of nine and as many as 15 different antileukemia drugs before enrollment. All patients had previously received one or more standard VCR therapies. Ongoing, pre-VSLI, neuropathy-related signs or symptoms including extremity pain (31%), areflexia (28%), constipation (17%), and hypoesthesia (14%) were present in 77% of patients, consistent with the prior VCR exposure. Four patients received at least one dose of hydroxyurea and 10 received a corticosteroid for leukocytosis control.
Patients received a median of four doses of VSLI (range, 1 to 18) with a median individual dose size of 4.12 mg (range, 3.14 to 5.51 mg).
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Median dose density was 2.25 mg/m 2 /week (range, 0.94 to 2.29 mg/ m 2 /week) and median cumulative VSLI exposure was 18.84 mg (range, 3.50 to 70.12 mg). Seventy-two percent of VSLI doses were administered in an outpatient setting.
Response
CR/CRi was achieved in 20% of patients (Table 2 ). An additional 15% of patients achieved a PR or BMB resulting in an overall response rate of 35%. Table 3 lists the 13 patients who achieved CR/CRi. Younger age and higher baseline platelet count were independently associated with a favorable response (P Ͻ .05). Patients with a baseline platelet count of greater than 50 ϫ 10 9 /L achieved a significantly higher CR/CRi rate (odds ratio, 5.5; 95% CI, 1.04 to 29.2). Time interval between last standard VCR exposure and VSLI treatment did not correlate with likelihood of response.
CR/CRi was achieved in 25% of patients with an untreated relapse and 14% of those with relapse that was refractory to one or more lines of single-agent (ie, clofarabine) or multiagent (eg, high-dose cytarabine plus methotrexate and vinorelbine, mitoxantrone, plus cytarabine) antileukemia therapy. The IRRC corroborated 11 CR/CRi and assessed the remaining two as BMB, based on available laboratory data.
The majority of patients (nine [69%] of 13) with a CR/CRi from VSLI had a response duration that exceeded the duration of response to their immediate prior line of ALL therapy. One patient who achieved CR/CRi relapsed approximately 15 months later and achieved a second CR following re-treatment with VSLI monotherapy on a compassionate basis.
Survival
As illustrated in Figure 1 , the OS rates were 89% (95% CI, 82 to 97) at 1 month, 35% (95% CI, 23 to 47) at 6 months, 8% (95% CI, 1 to 15) at 12 to 18 months, and 4% (95% CI, 0 to 9) at 24 months. Median OS, overall, was 4.6 months (range, Ͻ 1 month to Ͼ 25 months) and 7.7 months (range, 2.4 months to Ͼ 23.3 months) in those achieving CR/CRi. Five patients had an OS longer than 1 year. Two patients are still alive. Prognostic factors associated independently with more prolonged OS were younger age, Eastern Cooperative Oncology Group performance status 0 or 1, duration of first CR of 36 months or longer, baseline serum albumin of 3 g/L or higher, and baseline hemoglobin level of 10 g/dL or higher.
Stem-Cell Transplantation
Twelve (19%) patients underwent HCT after being treated with VSLI monotherapy; five patients after achieving CR/CRi, one after achieving a PR, one after a BMB, and five patients without a documented response. The seven responders with a post-VSLI HCT had a median OS of 8.9 months (range, 5.4 to Ͼ 23.3 months) with 86% surviving longer than 6 months, whereas the 16 responders without post-VSLI HCT had a median OS of 7.7 months (range, 2.4 to 22.0 months) with 63% surviving longer than 6 months. Overall, patients receiving transplantations had a median OS of 9.3 months (range, 4.0 to 25.3 months). Only 5% of VSLI nonresponders without post-VSLI HCT survived longer than 6 months.
MRD Assessment
Post-VSLI induction MRD data were available for 12 of the 13 patients who achieved CR/CRi. Molecular remission, based on MRD negativity, was confirmed in 67% (eight of 12 patients), including both CRi patients assessed as BMBs by the IRRC. Median response duration was 140 days (range, 32 to 162 days) in the MRD-negative group and 87 days (range, 35 to 210 days) in the MRD-positive group.
Safety
Treatment-related adverse events (AEs) occurring in at least 5% of patients are presented in Table 4 . Overall, 86% of patients had a neuropathy-associated AE. There was no significant pattern in the frequency or type of AE when evaluated by sex, race, or age.
Twenty-five patients (39%) experienced at least one grade 3 treatment-related AE, and 12 patients (19%) experienced at least one grade 4 treatment-related AE. Grade 3 peripheral neuropathy-related events combined (eg, hypoesthesia, hyporeflexia, neuropathy peripheral, limb pain, and motor weakness) were reported in 23% of patients. There was only one grade 4 peripheral neuropathy-related AE 
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Approximately one third of patients (32%) experienced at least one serious adverse event that was assessed as treatment-related. The most frequently occurring treatment-related serious adverse events were neuropathy peripheral (6%), febrile neutropenia (5%), tumor lysis syndrome (5%), and constipation (3%).
Sixty patients (92%) died during the study; 15 patients (23%) died during the treatment period and 45 patients (69%) died during the follow-up period (ie, more than 30 days following the last VSLI dose). The 30-day induction mortality rate was 12%. The most frequently occurring AEs resulting in death were ALL (12%), respiratory distress (5%), septic shock (3%), and cardiac arrest (3%). No neuropathy-associated AE led to death.
DISCUSSION
High-dose, once-per-week VSLI (2.25 mg/m 2 ) monotherapy delivered as third-, fourth-, fifth-, or seventh-line therapy to heavily pretreated and immunocompromised, adult patients with previously responsive, advanced, relapsed and refractory Ph-negative ALL resulted in an overall response rate of 35%, CR/CRi rate of 20%, and HCT bridging rate of 19% in conjunction with a predictable and manageable toxicity profile. Better than anticipated survival, consistent with that expected in the second-line therapy setting and not the third or greater line therapy, was attributed to a combination of meaningful single-agent efficacy and relatively low 30-day induction mortality rate. Demonstrated efficacy in patients with relapsed ALL refractory to clofarabine or vinca-alkaloid containing multiagent therapy and patients with relapse post-HCT is Overall survival and hematopoietic cell transplantation after vincristine sulfate liposome injection (post-VSLI HCT) among the 65 patients treated with VSLI monotherapy. The median overall survival in the 65 patients treated with VSLI monotherapy was 4.6 months, with 34% of patients living longer than 6 months. There were five long-term survivors (ie, survival for longer than 1 year) and two patients who remain alive and potentially represent cures. The median overall survival in responders (patients experiencing complete response, complete response with incomplete hematologic recovery, partial remission, and bone marrow blast response [CR ϩ CRi ϩ PR ϩ BMB]) was 7.7 months, with 70% of patients alive for longer than 6 months. Nonresponders had a median overall survival of 3.0 months, with 14% alive for longer than 6 months. The median overall survival in the 12 patients who underwent post-VSLI HCT was 9.3 months, with 83% alive for longer than 6 months. 11  17  5  8  5  8  Anemia  8  12  3  5  0  0  Thrombocytopenia  6  9  1  2  3  5  Febrile neutropenia  5  8  2  3  0  0  General disorders and  administration site conditions  16  25  5  8  0  0  Fatigue  7  11  2  3  0  0  Asthenia  6  9  2  3  0  0  Pyrexia  6  9  1  2  0  0  Metabolism and nutrition disorders  14  22  4  6  2  3  Decreased appetite  8  12  1  2  0  0  Tumor lysis syndrome  5  8  1  2  2  3  Investigations  12  19  5  8  1  2  Weight decreased  7  11  0  0  0  0 Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; ITT, intention-to-treat. testament to the antileukemia activity of VSLI. High-dose VSLI provided a generally well-tolerated and effective inpatient or outpatient salvage treatment option for patients with little else to be offered other than a purely comfort care management approach. 18 In addition to optimizing pharmacokinetics 19 and fostering enhanced target-tissue delivery, 11-13 the VSLI formulation facilitated VCR dose-intensification from 1.4 mg/m 2 , with a widely employed 2.0 mg cap, to 2.25 mg/m 2 , without a cap, without apparent toxicity exacerbation. VSLI delivered 1.57-to 2.76-fold as much VCR per dose as would have been delivered by a 2-mg dose of standard VCR. Combined with prolonged and sustained delivery to ALL target tissues, these increased doses were likely instrumental in overcoming any relative VCR resistance and inducing remissions. 20 Based on landmark investigations, primarily in lymphoma patients, VCR dose (ie, individual dose, cumulative dose, and dose density), clinical efficacy, and neurotoxicity have been inextricably linked. [21] [22] [23] [24] [25] [26] [27] Doses of standard VCR comparable to the doses of VSLI achieved in this study have been associated with almost universal grade 3 or greater neurotoxicity. 21 DeVita and Hubbard 24 reported that standard VCR at 1.4 mg/m 2 , without a dose cap (2.5 mg/dose average), delivered on days 1 and 8 of a 28-day cycle resulted in loss of deep tendon reflexes in 100% of patients. Dose reductions reduced the incidence and severity of toxicity but with a parallel reduction in CR and cure rates. The resultant practice of dose capping at 2.0 mg per infusion limits the dose, and potentially the efficacy, of standard VCR in adults with bodysurface area greater than 1.43 m 2 . 28 The standard VCR 2.0 mg dose cap remains today and is espoused in practice guidelines and employed in major cancer clinical trials.
The dose-reduction algorithm facilitated continued dosing, instead of treatment discontinuation, to achieve the highest possible cumulative VSLI dose and presumably a higher response rate. In striking contrast with past observations with standard VCR, individual dose reduction did not preclude nor reduce efficacy. In fact, of the 15 patients who underwent a dose reduction, seven patients (47%) achieved CR/CRi. MRD assessment may be of particular utility in the advanced, relapsed, and refractory ALL setting, in which CR determination may be challenging in patients with morphologic remission and incomplete recovery of either (ie, CRi) or both (ie, BMB) platelet count and neutrophil count because of extensive prior myelotoxic therapy.
In our study, once-per-week VSLI 2.25 mg/m 2 produced no new or unexpected toxicities and had a toxicity profile comparable to standard VCR at its labeled dose. This is noteworthy given the markedly higher VCR dosing afforded by VSLI and the high prevalence of baseline residual neuropathy. In a comprehensive evaluation of standard VCR-related neuropathy, Haim et al 29 reported a 92% neuropathy AE rate, 78% paraesthesia rate, and 16% grade 3 motor weakness rate as a result of standard VCR 1.4 mg/m 2 dosed every 21 days as part of a multidrug regimen. In our study, onceper-week VSLI 2.25 mg/m 2 monotherapy was related to a 63% neuropathy rate, 20% paraesthesia rate, and no incidence of grade 3 peripheral motor neuropathy. These AE rates likely reflect the successful use of the dose reduction algorithm.
There are no comparative phase 3 studies in advanced, relapsed, and refractory Ph-negative adult ALL patients. Experience is primarily limited to analyses of comparable populations from three small, phase II prospective studies and one large, single-institution, retrospective study. In a study of single-agent clofarabine, one (13%) of eight patients in need of third-line therapy achieved a short-lived CR. 30 A study of single-agent nelarabine reported CR in five (18%) of 28 patients exclusively with T-cell lineage ALL or lymphoblastic lymphoma. 31 An additional patient achieved a "CR*" which was equivalent to a BMB in this study. In a study of clofarabine plus cytarabine, 32 three (19%) of 16 patients in need of third-line or greater therapy achieved CR/CRi.
The retrospective study included a 56 patient subgroup with Ph-negative ALL treated with non-VSLI single-agents that represents the best historical comparison group for our study population. 3, 33 Single-agent therapy is often warranted because of a lack of standard multiagent regimens, poor response to prior multiagent therapy and HCT, or inability to tolerate additional multiagent therapy. This subgroup had a 4% (two of 56 patients) CR/CRi rate at the expense of a 30% (17 of 56 patients) 30-day mortality rate.
In summary, high-dose VSLI monotherapy resulted in meaningful clinical outcomes including durable responses and ability to bridge to HCT in a near end-stage adult ALL population desperately in need of new therapies. The toxicity profile of high-dose VSLI was predictable, manageable, and comparable to that of standard dose and formulation VCR despite the delivery of large, normally unachievable, individual and cumulative doses of VCR. Phase 3 studies in frontline adult ALL and frontline aggressive non-Hodgkin lymphoma, predicated on the current study and the successful combination of VSLI with other chemotherapies and rituximab in other phase II studies, 34, 35 are currently enrolling. Relationship between cumulative vincristine sulfate liposome injection (VSLI) exposure, worst grade of related peripheral neuropathy adverse events, and response. Each grade of VSLI-related peripheral neuropathy has two columns of data. The blue rectangles in the left-hand columns of data represent nonresponders. The blue diamonds in the right-hand columns of data represent patients who achieved a partial remission or bone marrow blast response. The gold diamonds represent patients who achieved complete response or complete response with incomplete hematologic recovery. Responses, including complete response or complete response with incomplete hematologic recovery, were achieved at each grade of related peripheral neuropathy. Application of the dose reduction algorithm was intended to manage grade 3 toxicity and continue dosing to achieve response.
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